ASML's stock price is dropping today after the semiconductor giant issued this critical warning about 2026
The Platinum Card is about to change. Amex's new fast-format airport lounge might be a sneak preview
Southwest Florida's housing market is undergoing a material home price correction—here's why
Windows 95's look and feel are more impressive than ever
Dutch semiconductor company ASML Holding N.V. (Nasdaq: ASML) reported its second-quarter 2025 results, beating on its most critical metrics, but its stock price is still declining in premarket trading. The reason? Executives made comments about its upcoming 2026 fiscal year that have investors concerned. Here's what you need to know.
The most important non-chip company in the chip industry
ASML Holding N.V. is headquartered in Veldhoven, Netherlands, and is arguably the most important technology company within Europe's borders. Given that ASML is critical to the world's chipmaking supply chain, the company is also one of the most important tech giants in the world.
ASML is not a chipmaker itself. However, it produced the machines that make the chips inside your devices. These machines are known as extreme ultraviolet lithography (EUV) photolithography machines, and they use light to etch patterns into the silicon wafers used in chipmaking.
While the world has several photolithography machine companies, ASML is the world's only maker of EUV photolithography machines. EUV technology is critical in the world's most advanced chips, including those made by Apple for its Apple Silicon chips and the chips produced by Nvidia, which are crucial for artificial intelligence servers.
ASML's customers include Nvidia and TSMC, the maker of Apple's chips. The Dutch company sells its EUV machines to these companies, enabling them to produce their own chips. As noted by CNBC, ASML's most advanced photolithography machines can be the size of a double-decker bus and cost as much as $400 million each.
Without ASML's machines, the world's semiconductor manufacturing capability grinds to a halt.
ASML beats, but 2026 comments worry investors
Thanks to the rise of artificial intelligence, chipmakers are pumping out more advanced chips than ever—chips that require the EUV photolithography machines that ASML offers. Given that, it's little surprise that ASML exceeded investor expectations in its most recent financial quarter.
Today, the company announced its Q2 2025 results, in which it reported:
€7.7 billion (about $8.9 billion) in net sales
€2.3 billion (about $2.6 billion) in net income
Gross margin of 53.7%
Earnings per share of €5.90 (about $6.85)
To put those net sales and net income figures into greater perspective, CNBC notes that analysts were expecting net sales of €7.52 billion (about $8.7 billion) and net income of €2.04 billion (about $2.3 billion).
In other words, ASML handily beat expectations.
The company also reported net bookings—a metric that indicates customer demand—of €5.5 billion (about $6.3 billion), of which €2.3 billion (about $2.6 billion) is for its most advanced EUV photolithography machines. Analysts had been expecting net bookings of €4.19 billion (about $4.8 billion).
Why is ASML stock falling?
However, despite the welcomed Q2 results, ASML's stock price has plunged in premarket trading after the company announced its latest financials. That fall has to do with two main factors.
First, ASML's Q3 forecast disappointed investors. The company said it expects to post total net sales of between €7.4 billion (about $8.6 billion) and €7.9 billion. It also expects its gross margin to be between 50% and 52% for the period. The company also said it expects its full fiscal 2025 total net sales to equate to an increase of 15%.
As noted by CNBC, analysts had been expecting Q3 net sales to be around €8.3 billion (about $9.1 billion). ASML's 15% growth forecast for full-year sales was also lower than what it had previously forecast.
However, the second factor may be the primary reason for ASML's share price decline this morning—comments made by ASML executives regarding its 2026 outlook.
Announcing its Q2 results, ASML CEO Christophe Fouquet touched on expectations for 2026.
'Looking at 2026, we see that our AI customers' fundamentals remain strong,' Fouquet said. 'At the same time, we continue to see increasing uncertainty driven by macro-economic and geopolitical developments. Therefore, while we still prepare for growth in 2026, we cannot confirm it at this stage.'
In other words, ASML's CEO is admitting he does not know if the company will grow in 2026. His comments suggest that the main uncertainty surrounding its growth potential are related to President Trump's tariffs.
ASML is a foreign company that sells a significant amount to American companies, yet it does not have widespread operations in America, making it a potential target for retaliation from Trump and his goal to bring manufacturing back to the United States.
Fouquet did not say there would not be growth, but given the tariff uncertainty, he seems to feel it's more prudent to prepare investors for that possibility.
But that's a cautionary message investors have not taken well.
As of the time of this writing, ASML shares are down over 7% in premarket trading to $764 per share. Yesterday, shares had closed above $823. As of yesterday's close, ASML shares were up over 18% since the beginning of the year.
This post originally appeared at fastcompany.comSubscribe to get the Fast Company newsletter: http://fastcompany.com/newsletters

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
10 minutes ago
- Business Upturn
PEPGEN (PEPG) ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Against PepGen and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options If you purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. ('PepGen' or the 'Company') (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the 'Class Period'). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ('FDA') approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times. If you purchased or otherwise acquired PepGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]


Business Upturn
10 minutes ago
- Business Upturn
TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Tempus between August 6, 2024 and May 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. ('Tempus' or the 'Company') (NASDAQ: TEM) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the 'Class Period'). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. If you purchased or otherwise acquired Tempus shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Yahoo
35 minutes ago
- Yahoo
Oppenheimer Trims Amazon (AMZN) Price Target to $245 — AI Growth Still a Bright Spot
Inc. (NASDAQ:AMZN) is one of the On August 1, Oppenheimer analyst Jason Helfstein lowered the price target on the stock to $245.00 (from $250.00) while maintaining an 'Outperform' rating. The rating affirmation comes amid frustrated investors over a lack of positive second half 2025 AWS commentary. This is because capacity issues are anticipated to persist until at least year-end. Nevertheless, CEO Jassy has reiterated that artificial intelligence is the 'the biggest technology transformation for a lifetime.' This is already evident considering AWS AI revenue is continuing to grow triple-digits year-over-year and its usage is still early within AWS. The firm doesn't see any consumer weakness despite tariff impacts remaining. Inc. (NASDAQ:AMZN) is an American technology company offering e-commerce, cloud computing, and other services, including digital streaming and artificial intelligence solutions. While we acknowledge the potential of AMZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Sign in to access your portfolio